综合分子剖析在患有肉瘤的青少年和年轻成年人的临床影响
Eden C Andrew1,2,3, Jeremy Lewin1,3,4, Jayesh Desai1,4
1Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia.
Journal of personalized medicine
|February 23, 2024
概括
患有肉瘤的青少年和年轻人 (AYA) 的综合分子分析 (CMP) 是可行的,并且具有临床价值. 这种方法确定了可操作的基因组变异,并为近一半的肉瘤患者提出了新的治疗建议.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 精准医学是一门精准的医学.
背景情况:
- 瘤是具有不良预后和有限治疗选择的侵袭性瘤,特别是在青少年和年轻人 (AYA) 中.
- 患有肉瘤的AYA代表了一个研究不足的人群,与其他年龄组相比,其生存率略有改善.
- 综合分子分析 (CMP) 为个性化治疗策略提供了一个潜在的途径.
研究的目的:
- 评估CMP在患有肉瘤的AYA中的可行性和临床影响.
- 评估针对性DNA测序和全基因组/转录组测序在这个患者群体中的有用性.
- 确定可操作的基因组变异率及其对治疗建议的影响.
主要方法:
- 对25名患有肉瘤的AYA进行了回顾性分析,他们接受了CMP.
- 利用大面板向DNA测序或全基因组和转录组测序.
- 一个分子瘤委员会确定了可采取行动的变体,临床医生反在报告后收集.
主要成果:
- CMP是可行的,平均周转时间为45天.
- 在56%的患者 (14/25) 中检测到潜在的可操作变体.
- 对48%的患者 (12/25) 确定了新的治疗建议,包括12%的生殖系变异 (3/25) 和1名患者的诊断变化.
结论:
- 对于患有肉瘤的AYA来说,CMP在临床上是有价值的和可行的.
- 建议将CMP整合到日常护理中,因为技术和周转时间有所改善.
- 分子分析可以指导个性化治疗策略,并改善患有肉瘤的AYA的治疗结果.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis
346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346


